Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C

Roberto F. Martínez-Macías, Paula Cordero-Pérez, Omar A. Juárez-Rodríguez, Carlos Y. Chen-López, Francisco M. Martínez-Carrillo, Gabriela Alarcón-Galván, Roberto Mercado-Hernández, Linda E. Muñoz-Espinosa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

© 2014 Annals of Hepatology. All rights reserved. Background: We compared mortality and complications of chronic hepatitis C between treated and untreated Mexican patients after long-term follow-up. We used a time-to-event analysis and identified the prognostic factors. Material and methods: Seventy-four patients with chronic hepatitis C were studied. They were ≥ 18 years of age and had a molecular diagnosis of chronic hepatitis C and ≥ 6 months of follow- up. Patients with neoplasia or those infected with human immunodeficiency virus or hepatitis B Virus were excluded. Kaplan-Meier analysis, log-rank test, annualized incidence per 100 person-years, and stepwise discriminant analysis were used to analyse mortality and complications. Results: The end-point of annualized incidence was lowest in sustained virological responders, intermediate in non-responders, and highest in untreated patients. The absence of treatment impacted adversely on cirrhosis development and the occurrence of portal hypertension and hepatic decompensation/hepatocellular carcinoma (logrank, p < 0.05). Diabetes impacted adversely on liver-related death/liver transplantation among untreated patients. Stepwise discriminant analysis showed that diabetes, high blood pressure, and no retreatment predicted cirrhosis development (eigenvalue ≥ 0.8; p < 0.05). A MELD score ≥ 18 and age ≥ 50 years predicted hepatic decompensation/hepatocellular carcinoma (eigenvalue < 0.8; p < 0.05). APRI ≥ 1.5 predicted mortality/liver transplantation and liver-related death/liver transplantation (eigenvalue < 0.8; p < 0.05). Conclusions: This is the first long-term study of chronic hepatitis C among Mexican patients. Treated patients showed less progression of liver disease. Treated patients showed less progression of liver disease; and older patients, those with metabolic comorbidities, with MELD score ≥ 18 and APRI ≥ 1.5 exhibited adverse effects.
Original languageEnglish
Pages (from-to)36-45
Number of pages10
JournalAnnals of Hepatology
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Interferons
Comorbidity
Liver Transplantation
Therapeutics
Liver
Discriminant Analysis
Mortality
Liver Diseases
Hepatocellular Carcinoma
Fibrosis
Retreatment
Incidence
Kaplan-Meier Estimate
Portal Hypertension
Gastroenterology
Hepatitis B virus
HIV
Hypertension

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Martínez-Macías, R. F., Cordero-Pérez, P., Juárez-Rodríguez, O. A., Chen-López, C. Y., Martínez-Carrillo, F. M., Alarcón-Galván, G., ... Muñoz-Espinosa, L. E. (2015). Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. Annals of Hepatology, 36-45.
Martínez-Macías, Roberto F. ; Cordero-Pérez, Paula ; Juárez-Rodríguez, Omar A. ; Chen-López, Carlos Y. ; Martínez-Carrillo, Francisco M. ; Alarcón-Galván, Gabriela ; Mercado-Hernández, Roberto ; Muñoz-Espinosa, Linda E. / Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. In: Annals of Hepatology. 2015 ; pp. 36-45.
@article{8c78a8383d6e4081b550032727614dde,
title = "Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C",
abstract = "{\circledC} 2014 Annals of Hepatology. All rights reserved. Background: We compared mortality and complications of chronic hepatitis C between treated and untreated Mexican patients after long-term follow-up. We used a time-to-event analysis and identified the prognostic factors. Material and methods: Seventy-four patients with chronic hepatitis C were studied. They were ≥ 18 years of age and had a molecular diagnosis of chronic hepatitis C and ≥ 6 months of follow- up. Patients with neoplasia or those infected with human immunodeficiency virus or hepatitis B Virus were excluded. Kaplan-Meier analysis, log-rank test, annualized incidence per 100 person-years, and stepwise discriminant analysis were used to analyse mortality and complications. Results: The end-point of annualized incidence was lowest in sustained virological responders, intermediate in non-responders, and highest in untreated patients. The absence of treatment impacted adversely on cirrhosis development and the occurrence of portal hypertension and hepatic decompensation/hepatocellular carcinoma (logrank, p < 0.05). Diabetes impacted adversely on liver-related death/liver transplantation among untreated patients. Stepwise discriminant analysis showed that diabetes, high blood pressure, and no retreatment predicted cirrhosis development (eigenvalue ≥ 0.8; p < 0.05). A MELD score ≥ 18 and age ≥ 50 years predicted hepatic decompensation/hepatocellular carcinoma (eigenvalue < 0.8; p < 0.05). APRI ≥ 1.5 predicted mortality/liver transplantation and liver-related death/liver transplantation (eigenvalue < 0.8; p < 0.05). Conclusions: This is the first long-term study of chronic hepatitis C among Mexican patients. Treated patients showed less progression of liver disease. Treated patients showed less progression of liver disease; and older patients, those with metabolic comorbidities, with MELD score ≥ 18 and APRI ≥ 1.5 exhibited adverse effects.",
author = "Mart{\'i}nez-Mac{\'i}as, {Roberto F.} and Paula Cordero-P{\'e}rez and Ju{\'a}rez-Rodr{\'i}guez, {Omar A.} and Chen-L{\'o}pez, {Carlos Y.} and Mart{\'i}nez-Carrillo, {Francisco M.} and Gabriela Alarc{\'o}n-Galv{\'a}n and Roberto Mercado-Hern{\'a}ndez and Mu{\~n}oz-Espinosa, {Linda E.}",
year = "2015",
month = "1",
day = "1",
language = "English",
pages = "36--45",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",

}

Martínez-Macías, RF, Cordero-Pérez, P, Juárez-Rodríguez, OA, Chen-López, CY, Martínez-Carrillo, FM, Alarcón-Galván, G, Mercado-Hernández, R & Muñoz-Espinosa, LE 2015, 'Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C', Annals of Hepatology, pp. 36-45.

Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. / Martínez-Macías, Roberto F.; Cordero-Pérez, Paula; Juárez-Rodríguez, Omar A.; Chen-López, Carlos Y.; Martínez-Carrillo, Francisco M.; Alarcón-Galván, Gabriela; Mercado-Hernández, Roberto; Muñoz-Espinosa, Linda E.

In: Annals of Hepatology, 01.01.2015, p. 36-45.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C

AU - Martínez-Macías, Roberto F.

AU - Cordero-Pérez, Paula

AU - Juárez-Rodríguez, Omar A.

AU - Chen-López, Carlos Y.

AU - Martínez-Carrillo, Francisco M.

AU - Alarcón-Galván, Gabriela

AU - Mercado-Hernández, Roberto

AU - Muñoz-Espinosa, Linda E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - © 2014 Annals of Hepatology. All rights reserved. Background: We compared mortality and complications of chronic hepatitis C between treated and untreated Mexican patients after long-term follow-up. We used a time-to-event analysis and identified the prognostic factors. Material and methods: Seventy-four patients with chronic hepatitis C were studied. They were ≥ 18 years of age and had a molecular diagnosis of chronic hepatitis C and ≥ 6 months of follow- up. Patients with neoplasia or those infected with human immunodeficiency virus or hepatitis B Virus were excluded. Kaplan-Meier analysis, log-rank test, annualized incidence per 100 person-years, and stepwise discriminant analysis were used to analyse mortality and complications. Results: The end-point of annualized incidence was lowest in sustained virological responders, intermediate in non-responders, and highest in untreated patients. The absence of treatment impacted adversely on cirrhosis development and the occurrence of portal hypertension and hepatic decompensation/hepatocellular carcinoma (logrank, p < 0.05). Diabetes impacted adversely on liver-related death/liver transplantation among untreated patients. Stepwise discriminant analysis showed that diabetes, high blood pressure, and no retreatment predicted cirrhosis development (eigenvalue ≥ 0.8; p < 0.05). A MELD score ≥ 18 and age ≥ 50 years predicted hepatic decompensation/hepatocellular carcinoma (eigenvalue < 0.8; p < 0.05). APRI ≥ 1.5 predicted mortality/liver transplantation and liver-related death/liver transplantation (eigenvalue < 0.8; p < 0.05). Conclusions: This is the first long-term study of chronic hepatitis C among Mexican patients. Treated patients showed less progression of liver disease. Treated patients showed less progression of liver disease; and older patients, those with metabolic comorbidities, with MELD score ≥ 18 and APRI ≥ 1.5 exhibited adverse effects.

AB - © 2014 Annals of Hepatology. All rights reserved. Background: We compared mortality and complications of chronic hepatitis C between treated and untreated Mexican patients after long-term follow-up. We used a time-to-event analysis and identified the prognostic factors. Material and methods: Seventy-four patients with chronic hepatitis C were studied. They were ≥ 18 years of age and had a molecular diagnosis of chronic hepatitis C and ≥ 6 months of follow- up. Patients with neoplasia or those infected with human immunodeficiency virus or hepatitis B Virus were excluded. Kaplan-Meier analysis, log-rank test, annualized incidence per 100 person-years, and stepwise discriminant analysis were used to analyse mortality and complications. Results: The end-point of annualized incidence was lowest in sustained virological responders, intermediate in non-responders, and highest in untreated patients. The absence of treatment impacted adversely on cirrhosis development and the occurrence of portal hypertension and hepatic decompensation/hepatocellular carcinoma (logrank, p < 0.05). Diabetes impacted adversely on liver-related death/liver transplantation among untreated patients. Stepwise discriminant analysis showed that diabetes, high blood pressure, and no retreatment predicted cirrhosis development (eigenvalue ≥ 0.8; p < 0.05). A MELD score ≥ 18 and age ≥ 50 years predicted hepatic decompensation/hepatocellular carcinoma (eigenvalue < 0.8; p < 0.05). APRI ≥ 1.5 predicted mortality/liver transplantation and liver-related death/liver transplantation (eigenvalue < 0.8; p < 0.05). Conclusions: This is the first long-term study of chronic hepatitis C among Mexican patients. Treated patients showed less progression of liver disease. Treated patients showed less progression of liver disease; and older patients, those with metabolic comorbidities, with MELD score ≥ 18 and APRI ≥ 1.5 exhibited adverse effects.

M3 - Article

SP - 36

EP - 45

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

ER -

Martínez-Macías RF, Cordero-Pérez P, Juárez-Rodríguez OA, Chen-López CY, Martínez-Carrillo FM, Alarcón-Galván G et al. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C. Annals of Hepatology. 2015 Jan 1;36-45.